An official website of the United States government
Home
Name
ara-C/MTX
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for ara-C/MTX
Name
Alternate Names
Amethopterin
Antifolan
CL-14377
Folex
Methotrexate Sodium
Mexate
Mexate AQ
Rheumatrex
WR-19039
Abbreviations
MTX
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
740
000740
Primary Site
Bladder cancer
Breast
Gestational trophoblastic cancer
lymphoma
Meningeal leukemia
Non-Hodgkin lymphoma
Osteogenic sarcoma
Histology
None
Remarks
FDA approved uses on ALL, breast cancer, choriocarcinoma, head and neck cancer, lymphoma, and osteosarcoma.
Coding
This drug should be coded
Name
Alternate Names
AC-1075
Alexan
Ara-cytidine
Arabinocytidine
Arabinosylcytosine
Beta-Arabinosylcytosine
Cytarabin
Cytarabine
Cytarabinoside
Cytosar
Cytosar-U
Cytosine Arabinoside
Cytosine arabinoside hydrochloride
Spongocytidine HCL
Tarabine
Tarabine PFS
U-19920
U-19920A
WR-28453
Abbreviations
ara-C
CA
HDA
HDARA-C
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
063878
63878
Primary Site
Histology
None
Remarks
Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)
Coding
This drug should be coded
Name
Alternate Names
G-CSF
GCSF
Neupogen
Recombinant human granulocyte colony-stimulating factor
Zarxio
r-G-CSF
r-met Hu G-CSF
rhG-CSF
Abbreviations
None
Category
Ancillary Agent
Subcategory
None
NSC Number
614371
614629
Primary Site
None
Histology
None
Remarks
A granulocyte colony-stimulating factor (G-CSF). Adjunct of Ganciclovir therapy; treatment of neutropenia
March 2015: Zarxio is the first biosimilar product approved in the United States. A biosimilar product is a biological product that is based on a showing that it is highly similar to an already-approved biological product, known as a reference product. There are no differences in terms of safety and effectiveness from the reference product (neupogen)
March 2015: Zarxio is the first biosimilar product approved in the United States. A biosimilar product is a biological product that is based on a showing that it is highly similar to an already-approved biological product, known as a reference product. There are no differences in terms of safety and effectiveness from the reference product (neupogen)
Coding
This drug should NOT be coded
